TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Sponsor
Fujian Cancer Hospital
Study ID
NCT05314101
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Tislelizumab — DRUG
    Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
  • bevacizumab — DRUG
    Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
  • TAS-102 — DRUG
    Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks

Study Details

To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.

Key Dates

First listed
Apr 6, 2022
Start date
Apr 1, 2022
Status verified
Mar 2022
Primary completion
Feb 28, 2023
Completion
Feb 28, 2024

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TAS-102 combined with bevacizumab and tislelizumab
    TAS-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer

Primary Outcome Measure

progression free survival [ Time Frame: up to 24 months ]

Central Contacts

Related Studies